Elotuzumab is a recombinant humanized monoclonal antibody and an immunostimulatory therapeutic agent used in combination with other medicines for the treatment of multiple myeloma.
Elotuzumab specifically targets Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7), a cell-surface protein expressed on multiple myeloma cells and natural killer (NK) cells. By binding to SLAMF7, elotuzumab can facilitate immune-mediated recognition and destruction of myeloma cells.
Elotuzumab is a biological pharmaceutical active ingredient rather than a conventional small-molecule API. Therefore, its characterization requires specialized biologic analytical methods, including protein identity, purity, aggregation, glycosylation and biological activity testing.
Elotuzumab is relevant to the development and manufacture of monoclonal-antibody-based therapies for multiple myeloma. As a recombinant antibody, its quality assessment requires control of critical quality attributes such as molecular integrity, purity, charge variants, glycosylation profile, aggregates and biological potency.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |